Current status of research on the genetic susceptibility of primary biliary cholangitis

Chunmei ZHAO; Di MA; Wenlin TAI

doi:10.12449/JCH240328

Volume 40 Issue 3

Mar. 2024

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(3): 606-610

PDF( 613 KB)

Current status of research on the genetic susceptibility of primary biliary cholangitis

DOI: 10.12449/JCH240328

Department of Clinical Laboratory，The Second Affiliated Hospital of Kunming Medical University，Kunming 650032，China

Research funding:

National Natural Science Foundation of China (82060385);

Postgraduate Innovation Fund of Kunming Medical University in 2023 (2023S321)

More Information

Corresponding author: TAI Wenlin， taiwenlinlin@sohu.com （ORCID： 0000-0002-8278-929X）
Received Date: 2023-06-27
Accepted Date: 2023-07-20
Published Date: 2024-03-20

Abstract

Abstract

Primary biliary cholangitis （PBC） is a liver autoimmune disease with a strong genetic tendency characterized by the degeneration and necrosis of bile duct epithelial cells， and it is often observed in middle-aged and elderly women. With the continuous development of genome-wide association studies， the genetic susceptibility of PBC has attracted more and more attention. This article elaborates on the research advances in the genetic susceptibility genes closely associated with PBC， in order to provide effective targets for the treatment of PBC.
- Primary Biliary Cholangitis,
- Genetic Predisposition to Disease,
- HLA Antigens

FullText(HTML)

References(50)

References

[1]	YANG HQ, CHEN LL, LIU YH. A large-scale plasma proteome Mendelian randomization study identifies novel causal plasma proteins related to primary biliary cholangitis[J]. Front Immunol, 2023, 14: 1052616. DOI: 10.3389/fimmu.2023.1052616.
[2]	YOU H, MA X, EFE C, et al. APASL clinical practice guidance: The diagnosis and management of patients with primary biliary cholangitis[J]. Hepatol Int, 2022, 16( 1): 1- 23. DOI: 10.1007/s12072-021-10276-6.
[3]	AHOUSSOUGBEMEY MELE A, MAHMOOD R, OGBUAGU H, et al. Hyperlipidemia in the setting of primary biliary cholangitis: A case report and review of management strategies[J]. Cureus, 2022, 14( 11): e31411. DOI: 10.7759/cureus.31411.
[4]	COLAPIETRO F, LLEO A, GENERALI E. Antimitochondrial antibodies: From bench to bedside[J]. Clin Rev Allergy Immunol, 2022, 63( 2): 166- 177. DOI: 10.1007/s12016-021-08904-y.
[5]	QIAN Q, HE W, TANG R, et al. Implications of gut microbiota in autoimmune liver diseases[J]. Minerva Gastroenterol(Torino), 2023, 69( 1): 95- 106. DOI: 10.23736/S2724-5985.21.02860-9.
[6]	ÖRNOLFSSON KT, OLAFSSON S, BERGMANN OM, et al. Using the Icelandic genealogical database to define the familial risk of primary biliary cholangitis[J]. Hepatology, 2018, 68( 1): 166- 171. DOI: 10.1002/hep.29675.
[7]	SELMI C, MAYO MJ, BACH N, et al. Primary billiary cirrhosis in monozygotic twins: genetics, epigenetics, and environment[J]. Gastroenterology, 2004, 127( 2): 485- 492. DOI: 10.1053/j.gastro.2004.05.005.
[8]	ALWABEL AH, PEEDIKAYIL M, ALNASSER S, et al. Efficacy of ursodeoxycholic acid for primary biliary cholangitis: Experience from a tertiary care centre in Saudi Arabia[J]. Saudi J Gastroenterol, 2023, 29( 2): 135- 140. DOI: 10.4103/sjg.sjg_445_21.
[9]	GERUSSI A, CRISTOFERI L, CARBONE M, et al. The immunobiology of female predominance in primary biliary cholangitis[J]. J Autoimmun, 2018, 95: 124- 132. DOI: 10.1016/j.jaut.2018.10.015.
[10]	GOLDEN LC, ITOH Y, ITOH N, et al. Parent-of-origin differences in DNA methylation of X chromosome genes in T lymphocytes[J]. PNAS, 2019, 116( 52): 26779- 26787. DOI: 10.1073/pnas.1910072116.
[11]	CAO H, ZHU BK, QU Y, et al. Abnormal expression of ERα in cholangiocytes of patients with primary biliary cholangitis mediated intrahepatic bile duct inflammation[J]. Front Immunol, 2019, 10: 2815. DOI: 10.3389/fimmu.2019.02815.
[12]	QIU F, TANG RQ, ZUO XB, et al. A genome-wide association study identifies six novel risk loci for primary biliary cholangitis[J]. Nat Commun, 2017, 8: 14828. DOI: 10.1038/ncomms14828.
[13]	LI Y, LI ZQ, CHEN RL, et al. A regulatory variant at 19p13.3 is associated with primary biliary cholangitis risk and ARID3A expression[J]. Nat Commun, 2023, 14: 1732. DOI: 10.1038/s41467-023-37213-5.
[14]	CORDELL HJ, FRYETT JJ, UENO K, et al. Corrigendum to:“An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs”[J Hepatol 75(2021) 572-581][J]. J Hepatol, 2023, 78( 4): 883. DOI: 10.1016/j.jhep.2022.12.001.
[15]	DONG M, LI JX, TANG RQ, et al. Multiple genetic variants associated with primary biliary cirrhosis in a Han Chinese population[J]. Clin Rev Allergy Immunol, 2015, 48( 2-3): 316- 321. DOI: 10.1007/s12016-015-8472-0.
[16]	HITOMI Y, NAKAMURA M. The genetics of primary biliary cholangitis: A GWAS and post-GWAS update[J]. Genes, 2023, 14( 2): 405. DOI: 10.3390/genes14020405.
[17]	HUANG YQ. Recent advances in the diagnosis and treatment of primary biliary cholangitis[J]. World J Hepatol, 2016, 8( 33): 1419. DOI: 10.4254/wjh.v8.i33.1419.
[18]	JOSHITA S, UMEMURA T, TANAKA E, et al. Genetics and epigenetics in the pathogenesis of primary biliary cholangitis[J]. Clin J Gastroenterol, 2018, 11( 1): 11- 18. DOI: 10.1007/s12328-017-0799-z.
[19]	CHUNG BK, GUEVEL BT, REYNOLDS GM, et al. Phenotyping and auto-antibody production by liver-infiltrating B cells in primary sclerosing cholangitis and primary biliary cholangitis[J]. J Autoimmun, 2017, 77: 45- 54. DOI: 10.1016/j.jaut.2016.10.003.
[20]	DARLAY R, AYERS KL, MELLS GF, et al. Amino acid residues in five separate HLA genes can explain most of the known associations between the MHC and primary biliary cholangitis[J]. PLoS Genet, 2018, 14( 12): e1007833. DOI: 10.1371/journal.pgen.1007833.
[21]	LIU X, INVERNIZZI P, LU Y, et al. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis[J]. Nat Genet, 2010, 42( 8): 658- 660. DOI: 10.1038/ng.627.
[22]	WANG C, ZHENG XD, TANG RQ, et al. Fine mapping of the MHC region identifies major independent variants associated with Han Chinese primary biliary cholangitis[J]. J Autoimmun, 2020, 107: 102372. DOI: 10.1016/j.jaut.2019.102372.
[23]	GERUSSI A, CARBONE M, CORPECHOT C, et al. The genetic architecture of primary biliary cholangitis[J]. Eur J Med Genet, 2021, 64( 9): 104292. DOI: 10.1016/j.ejmg.2021.104292.
[24]	LI YN, LIU X, WANG Y, et al. Novel HLA-DRB1 alleles contribute risk for disease susceptibility in primary biliary cholangitis[J]. Dig Liver Dis, 2022, 54( 2): 228- 236. DOI: 10.1016/j.dld.2021.04.010.
[25]	TANAKA A, LEUNG PSC, GERSHWIN ME. The genetics of primary biliary cholangitis[J]. Curr Opin Gastroenterol, 2019, 35( 2): 93- 98. DOI: 10.1097/MOG.0000000000000507.
[26]	CHOW IT, JAMES EA, GATES TJ, et al. Differential binding of pyruvate dehydrogenase complex-E2 epitopes by DRB108∶‍01 and DRB111∶01 is predicted by their structural motifs and correlates with disease risk[J]. J Immunol, 2013, 190( 9): 4516- 4524. DOI: 10.4049/jimmunol.1202445.
[27]	HUANG CY, ZHANG HP, HAN WJ, et al. Disease predisposition of human leukocyte antigen class II genes influences the gut microbiota composition in patients with primary biliary cholangitis[J]. Front Immunol, 2022, 13: 984697. DOI: 10.3389/fimmu.2022.984697.
[28]	GUO F, HAO YA, ZHANG L, et al. Asthma susceptibility gene ORMDL3 promotes autophagy in human bronchial epithelium[J]. Am J Respir Cell Mol Biol, 2022, 66( 6): 661- 670. DOI: 10.1165/rcmb.2021-0305oc.
[29]	JAMES BN, WEIGEL C, GREEN CD, et al. Neutrophilia in severe asthma is reduced in Ormdl3 overexpressing mice[J]. FASEB J, 2023, 37( 3): e22799. DOI: 10.1096/fj.202201821R.
[30]	CHEN R, MICHAELOUDES C, LIANG YM, et al. ORMDL3 regulates cigarette smoke-induced endoplasmic reticulum stress in airway smooth muscle cells[J]. J Allergy Clin Immunol, 2022, 149( 4): 1445- 1457. e 5. DOI: 10.1016/j.jaci.2021.09.028.
[31]	XIANG BY, DENG CY, QIU F, et al. Single cell sequencing analysis identifies genetics-modulated ORMDL3⁺ cholangiocytes having higher metabolic effects on primary biliary cholangitis[J]. J Nanobiotechnol, 2021, 19( 1): 1- 21. DOI: 10.1186/s12951-021-01154-2.
[32]	SCHMIEDEL BJ, SEUMOIS G, SAMANIEGO-CASTRUITA D, et al. 17q21 asthma-risk variants switch CTCF binding and regulate IL-2 production by T cells[J]. Nat Commun, 2016, 7: 13426. DOI: 10.1038/ncomms13426.
[33]	ZHANG YT, ZENG WH, XIA YM. TWEAK/Fn14 axis is an important player in fibrosis[J]. J Cell Physiol, 2021, 236( 5): 3304- 3316. DOI: 10.1002/jcp.30089.
[34]	POVEDA J, VÁZQUEZ-SÁNCHEZ S, SANZ AB, et al. TWEAK-Fn14as a common pathway in the heart and the kidneys in cardiorenal syndrome[J]. J Pathol, 2021: path. 5631. DOI: 10.1002/path.5631.
[35]	PASCOE AL, JOHNSTON AJ, MURPHY RM. Controversies in TWEAK-Fn14 signaling in skeletal muscle atrophy and regeneration[J]. Cell Mol Life Sci, 2020, 77( 17): 3369- 3381. DOI: 10.1007/s00018-020-03495-x.
[36]	LIAO M, LIAO JW, QU JQ, et al. Hepatic TNFRSF12A promotes bile acid-induced hepatocyte pyroptosis through NFκB/Caspase-1/GSDMD signaling in cholestasis[J]. Cell Death Discov, 2023, 9: 26. DOI: 10.1038/s41420-023-01326-z.
[37]	WANG GY, GARCIA V, LEE J, et al. Nrf2 deficiency causes hepatocyte dedifferentiation and reduced albumin production in an experimental extrahepatic cholestasis model[J]. PLoS One, 2022, 17( 6): e0269383. DOI: 10.1371/journal.pone.0269383.
[38]	WANG N, CHEN P, SONG Y, et al. CD226 deficiency attenuates the homeostasis and suppressive capacity of Tr1 cells[J]. Mol Immunol, 2021, 132: 192- 198. DOI: 10.1016/j.molimm.2021.01.002.
[39]	BAI LF, JIANG JY, LI H, et al. Role of CD226 Rs763361 polymorphism in susceptibility to multiple autoimmune diseases[J]. Immunol Investig, 2020, 49( 8): 926- 942. DOI: 10.1080/08820139.2019.1703737.
[40]	CORDELL HJ, FRYETT JJ, UENO K, et al. An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs[J]. J Hepatol, 2021, 75( 3): 572- 581. DOI: 10.1016/j.jhep.2021.04.055.
[41]	TANAKA A, LEUNG PSC, YOUNG HA, et al. Therapeutic and immunological interventions in primary biliary cholangitis: From mouse models to humans[J]. Arch Med Sci, 2018, 14( 4): 930- 940. DOI: 10.5114/aoms.2017.70995.
[42]	SUN QN, WANG QA, FENG N, et al. The expression and clinical significance of serum IL-17 in patients with primary biliary cirrhosis[J]. Ann Transl Med, 2019, 7( 16): 389. DOI: 10.21037/atm.2019.07.100.
[43]	DENG CW, LI WL, FEI YY, et al. Imbalance of the CD226/TIGIT immune checkpoint is involved in the pathogenesis of primary biliary cholangitis[J]. Front Immunol, 2020, 11: 1619. DOI: 10.3389/fimmu.2020.01619.
[44]	DOUGALL WC, KURTULUS S, SMYTH MJ, et al. TIGIT and CD96: New checkpoint receptor targets for cancer immunotherapy[J]. Immunol Rev, 2017, 276( 1): 112- 120. DOI: 10.1111/imr.12518.
[45]	ADAM L, ZOLDAN K, HOFMANN M, et al. Follicular T helper cell signatures in primary biliary cholangitis and primary sclerosing cholangitis[J]. Hepatol Commun, 2018, 2( 9): 1051- 1063. DOI: 10.1002/hep4.1226.
[46]	LI YY, WANG WB, TANG LB, et al. Chemokine(C-X-C motif) ligand 13 promotes intrahepatic chemokine(C-X-C motif) receptor 5+ lymphocyte homing and aberrant B-cell immune responses in primary biliary cirrhosis[J]. Hepatology, 2015, 61( 6): 1998- 2007. DOI: 10.1002/hep.27725.
[47]	ZHOU ZQ, TONG DN, GUAN J, et al. Circulating follicular helper T cells presented distinctively different responses toward bacterial antigens in primary biliary cholangitis[J]. Int Immunopharmacol, 2017, 51: 76- 81. DOI: 10.1016/j.intimp.2017.08.004.
[48]	CIRULLI ET, GOLDSTEIN DB. Uncovering the roles of rare variants in common disease through whole-genome sequencing[J]. Nat Rev Genet, 2010, 11( 6): 415- 425. DOI: 10.1038/nrg2779.
[49]	KUKSA PP, GREENFEST-ALLEN E, CIFELLO J, et al. Scalable approaches for functional analyses of whole-genome sequencing non-coding variants[J]. Hum Mol Genet, 2022, 31( R1): R62- R72. DOI: 10.1093/hmg/ddac191.
[50]	HIRSCHFIELD GM, CHAPMAN RW, KARLSEN TH, et al. The genetics of complex cholestatic disorders[J]. Gastroenterology, 2013, 144( 7): 1357- 1374. DOI: 10.1053/j.gastro.2013.03.053.

Relative Articles

[1]	Professional Committee for Prevention and Control of Hepatobiliary and Pancreatic Diseases of Chinese Preventive Medicine Association， Chinese Society of Liver Cancer， Liver Study Group of Surgery Committee of Beijing Medical Association， et al. Expert consensus on the sequential surgery following conversion therapy based on the combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition)[J]. Journal of Clinical Hepatology, 2025, 41(1): 30-40. doi: 10.3760/cma.j.cn113884-20240814-00245
[2]	Shichun LU. Challenges and reflections on conversion therapy for advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(9): 1738-1740. doi: 10.12449/JCH240904
[3]	Bin YAN, Gexi CAO, Yanru DENG, Ying LI, Zhanjun DONG, Wanjun BAI. Effect of amlodipine and levamlodipine on the pharmacokinetics of lenvatinib in rats and related mechanisms[J]. Journal of Clinical Hepatology, 2024, 40(11): 2246-2252. doi: 10.12449/JCH241118
[4]	Xiaomeng YAO, Keke SUN, Yunkai LIN, Hui WANG, Liwei DONG, Lei CHEN, Heping HU. Molecular mechanism of lenvatinib resistance in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(12): 2524-2530. doi: 10.12449/JCH241225
[5]	Wei SUN, Xiaoyan DING, Jinglong CHEN. Efficacy and safety of anti-PD-1 monoclonal antibody combined with sorafenib or lenvatinib in treatment of patients with Child-Pugh class B unresectable hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(5): 975-981. doi: 10.12449/JCH240517
[6]	Hong NIE, Binyan ZHONG, Jian SHEN, Xiaoli ZHU. Efficacy and safety of tyrosine kinase inhibitor combined with immune checkpoint inhibitor as the second-line therapy for advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(8): 1620-1626. doi: 10.12449/JCH240818
[7]	Changwang ZHANG, Ninghan WU, Cong WANG, Zheng ZHENG, Siming GAO, Changpeng ZOU, Sujing ZHANG, Na LI. Efficacy and safety of cryoablation combined with Camrelizumab monoclonal antibody in treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(6): 1169-1174. doi: 10.12449/JCH240616
[8]	Shun CHEN, Youcheng XIE, Junke WANG, Baoyin ZHAO, Jiucong ZHANG, Pan WANG, Xiaohui YU. Association between immune checkpoint inhibitor antitumor therapy and hepatitis B virus reactivation[J]. Journal of Clinical Hepatology, 2023, 39(6): 1424-1430. doi: 10.3969/j.issn.1001-5256.2023.06.027
[9]	Xingshu ZHU, Pengfei CHEN, Mengfan ZHANG, Fangzheng LI, Jinwei CHEN, Wenguang ZHANG, Xuhua DUAN, Jianzhuang REN, Xinwei HAN. Efficacy and safety of ¹²⁵I intraluminal irradiation combined with lenvatinib in treatment of progressive extrahepatic cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2023, 39(10): 2406-2412. doi: 10.3969/j.issn.1001-5256.2023.10.019
[10]	Youcheng XIE, Shun CHEN, Chuyi LI, Ying ZHENG, Dong JIA, Jiucong ZHANG, Xiaohui YU. Application of immune checkpoint inhibitors in liver transplantation for patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(4): 941-947. doi: 10.3969/j.issn.1001-5256.2023.04.030
[11]	Yucheng HOU, Hongqiang ZHAO, Caoer DONG, Guangdong WU, Xuan TONG, Ang LI, Qian LU, Hong CHEN, Rui TANG. Research advances in immune checkpoint inhibitor-related cholangitis[J]. Journal of Clinical Hepatology, 2023, 39(2): 463-468. doi: 10.3969/j.issn.1001-5256.2023.02.034
[12]	Xiaoyan DING, Wei SUN, Yanjun SHEN, Ying TENG, Yawen XU, Wendong LI, Jinglong CHEN. Efficacy and safety of lenvatinib combined with sintilimab as the second-line therapy for intrahepatic cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2022, 38(8): 1813-1818. doi: 10.3969/j.issn.1001-5256.2022.08.018
[13]	Dan LIU, Tiantian YAO, Yuhan ZHANG, Guiqiang WANG, Yan WANG. Efficiency and safety of immune checkpoint inhibitors in cancer patients with chronic liver disease: A systematic review[J]. Journal of Clinical Hepatology, 2022, 38(11): 2457-2461. doi: 10.3969/j.issn.1001-5256.2022.11.005
[14]	Xiaomin LIU, Wei SUN, Jianying WEI, Wendong LI, Xiaoyan DING, Minghua YU, Jinglong CHEN. Efficacy and safety of lenvatinib in patients with unresectable hepatocellular carcinoma previously treated with tyrosine kinase inhibitor[J]. Journal of Clinical Hepatology, 2022, 38(6): 1323-1327. doi: 10.3969/j.issn.1001-5256.2022.06.020
[15]	Zhaoyue WANG, Lai WEI, Yuan HUANG. Advances in the application of programmed death-1/programmed death-ligand 1 inhibitors in the treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(2): 437-443. doi: 10.3969/j.issn.1001-5256.2021.02.040
[16]	Xiaoquan JI, Aimin ZHANG, Tao ZHANG, Wengang LI, Weiping HE, Jing SUN, Xuezhang DUAN. Efficacy and safety of sequential lenvatinib therapy after stereotactic body radiotherapy in treatment of advanced primary liver cancer[J]. Journal of Clinical Hepatology, 2021, 37(9): 2120-2124. doi: 10.3969/j.issn.1001-5256.2021.09.023
[17]	Ying TENG, Xiaoyan DING, Wendong LI, Jinglong CHEN. Clinical effect of programmed cell death-1 inhibitor combined with lenvatinib in treatment of advanced primary liver cancer and related adverse events[J]. Journal of Clinical Hepatology, 2021, 37(3): 606-610. doi: 10.3969/j.issn.1001-5256.2021.03.020
[18]	Sun Tao, Ren YanQiao, Cao YanYan, Zheng ChuanSheng. Advances in immune checkpoint inhibitor combined with other treatment methods for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(6): 1386-1388. doi: 10.3969/j.issn.1001-5256.2020.06.043
[19]	Li GuangXin, Zhang Yu, Yang YanMei, Wang Yi, Li Gong. Efficacy and safety of lenvatinib for unresectable,advanced hepatocellular carcinoma in a real-world setting[J]. Journal of Clinical Hepatology, 2020, 36(10): 2266-2269. doi: 10.3969/j.issn.1001-5256.2020.10.021
[20]	Ni MingLi. Clinical effect of transcatheter arterial chemoembolization combined with argon-helium cryoablation in patients with advanced unresectable primary hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2015, 31(1): 99-102. doi: 10.3969/j.issn.1001-5256.2015.01.021

Supplements(0)

Cited By

Cited by
Periodical cited type(1)
1. 蒋伊雯，戴正皓，郭航，陆雨婷，钟李长，梁涛. 剪切波弹性成像超声在男性前尿道狭窄中的应用. 中国医师杂志. 2024(12): 1808-1811 .
Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(1)

Get Citation

PDF

XML

Article Metrics

Article views (364) PDF downloads(49)

Current status of research on the genetic susceptibility of primary biliary cholangitis

DOI: 10.12449/JCH240328

Abstract

References

Relative Articles

Cited by

Periodical cited type(1)

Other cited types(1)

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Current status of research on the genetic susceptibility of primary biliary cholangitis

DOI: 10.12449/JCH240328

Abstract

References

Relative Articles

Cited by

Periodical cited type(1)

Other cited types(1)

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content